A pre-revenue biotech firm developing peptide therapeutics for autoimmune conditions like Type 1 diabetes, currently funded by a $83.4M capital base while burning cash at approximately $5.6M annually.
Decoy Therapeutics offers exposure to the promising field of peptide therapeutics for Type 1 diabetes with a unique mechanism of action that avoids broad immunosuppression; The company has secured substantial paid-in capital of $83.4M which provides a buffer against current cash burn and potential future clinical milestones; Early-stage biotech stocks with differentiated platforms can generate outsized returns upon successful regulatory approval.
The company carries no revenue and operates at a significant loss, requiring continuous capital infusion that is unsustainable without further dilution or partnership deals; With total assets of only $3.0M and a retained earnings deficit of $81.9M, the financial runway is extremely precarious; Investors face high risk of total capital loss given the binary nature of clinical trial outcomes and lack of commercial product pipeline.
Decoy Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune diseases, primarily targeting Type 1 diabetes and rheumatoid arthritis. The company leverages proprietary peptide-based technologies to modulate the immune system without affecting overall immunity. Currently operating in the specialized clinical research market with no commercial revenue generated yet.
The company reported a net loss of $5.6M in 2024, reflecting continued heavy investment in research and development totaling roughly $1.3M alongside general administrative costs of $5.0M. Cash flow from operations was negative $4.5M, resulting in a net cash decrease of $3.5M year-over-year while maintaining a positive financing cash flow of $1.1M through capital raises.
The biopharmaceutical industry for autoimmune diseases is highly competitive with large incumbents like Pfizer and Eli Lilly dominating the market, yet offering significant opportunities for novel mechanisms that avoid current limitations. Clinical-stage companies face intense scrutiny from regulators regarding safety profiles in early-stage trials. The sector requires substantial R&D investment where most failures occur before reaching commercialization.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $31.8M | $12.9M | $5.7M |
| Operating Income | $-31.8M | $-12.9M | $-5.7M |
| R&D | $15.8M | $7.2M | $770.0K |
| G&A | $7.1M | $5.7M | $5.0M |
| Stock-Based Comp | $796.8K | $524.8K | $273.7K |
| D&A | $6.7K | $10.1K | $4.4K |
| Other OpEx | $8.9M | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-31.8M | $-12.9M | $-5.7M |
| Income Tax | $-233.2K | $-352.3K | $-158.5K |
| Continuing Ops | $-31.6M | $-12.5M | $-5.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-31.6M | $-12.5M | $-5.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-31.6M | $-12.5M | $-5.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $14.5M | $6.5M | $3.0M |
| Cash & Equivalents | $12.1M | $5.9M | $2.4M |
| Prepaid Expenses | $803.4K | $619.8K | $553.0K |
| Other Current Assets | $1.6M | $0 | $0 |
| Long-Term Assets | $130.5K | $66.8K | $35.4K |
| Goodwill | $0 | — | — |
| Other LT Assets | $130.5K | — | — |
| Total Assets | $14.7M | $6.6M | $3.0M |
| Accounts Payable | $2.9M | $602.9K | $937.0K |
| Total Liabilities | $4.3M | $1.3M | $1.5M |
| Shareholders' Equity | $10.4M | $5.3M | $1.5M |
| Paid-In Capital | $74.2M | $81.6M | $83.4M |
| Retained Earnings | $-63.8M | $-76.3M | $-81.9M |
| Total L&E | $14.7M | $6.6M | $3.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-31.6M | $-12.5M | $-5.6M |
| Non-Cash Adjustments | $12.0M | $5.2M | $1.3M |
| Working Capital Changes | $2.0M | $-5.5M | $-212.7K |
| Cash from Operations | $-17.6M | $-12.8M | $-4.5M |
| Cash from Investing | $-1.5M | $0 | $0 |
| Cash from Financing | $2.0M | $6.6M | $1.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-17.1M | $-6.2M | $-3.5M |
| Beginning Cash | $29.2M | $12.1M | $5.9M |
| Ending Cash | $12.1M | $5.9M | $2.4M |
The company's financials reflect a single primary segment focused on clinical-stage drug development for autoimmune diseases, with no commercial product revenue streams yet active; all operating expenses are directed toward research and development activities.
Complete lack of commercial revenue and reliance on external financing to fund ongoing operations; Significant cash burn rate of $5.6M annually with limited current assets of only $3.0M; High probability of clinical trial failure or regulatory rejection typical for early-stage biotech firms; Potential dilution from equity issuance required to sustain operations.
Proprietary peptide-based technology platform capable of modulating specific immune pathways without compromising general immunity; Strong balance sheet with $83.4M in paid-in capital providing runway for clinical trials; Strategic focus on unmet medical needs in the high-value Type 1 diabetes market.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.